Phase II study of taselisib (GDC-0032) plus fulvestrant in HER2-negative, hormone receptor-positive advanced breast cancer: Analysis by PIK3CA and ESR1 mutation status from circulating tumor DNA

被引：1
|
作者：
Dickler, M. N.
Saura, C.
Oliveira, M.
Richards, D. A.
Krop, I. E.
Cervantes, A.
Stout, T. J.
Jin, H.
Savage, H. M.
Wilson, T. R.
Baselga, J.
机构：
[1] Mem Sloan Kettering Canc Ctr, Mem Hosp, 1275 York Ave, New York, NY 10021 USA
[2] Vall Hebron Univ Hosp, Vall Hebron Inst Oncol, Barcelona, Spain
[3] US Oncol Res, The Woodlands, TX USA
[4] Dana Farber Canc Inst, Boston, MA USA
[5] Univ Valencia, Inst Hlth Res INCLIVA, Valencia, Spain
[6] Genentech Inc, San Francisco, CA 94080 USA
来源：
CANCER RESEARCH | 2017年 / 77卷
关键词：
D O I：
10.1158/1538-7445.SABCS16-P6-12-01
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P6-12-01
引用
收藏
页数：2
相关论文
共 50 条
  • [31] LORELEI: A Phase II randomized, double-blind study of neoadjuvant letrozole plus taselisib (GDC-0032) versus letrozole plus placebo in postmenopausal women with ER-positive/HER2-negative, early stage breast cancer
    Saura, Cristina
    de Azambuja, Evandro
    Dubsky, Peter
    Oliveira, Mafalda
    Saini, Kamal S.
    Fes, Christian
    Lin, Ray S.
    Wilson, Timothy R.
    Fredickson, Jill
    Parmar, Hema
    Hsu, Jerry Y.
    Piccard, Martine
    Gnant, Michael
    Baselga, Jose
    CANCER RESEARCH, 2015, 75
  • [32] Alpelisib for the treatment of PIK3CA-mutated, hormone receptor-positive, HER2-negative metastatic breast cancer
    Leenhardt, Fanny
    Alexandre, Marie
    Jacot, William
    EXPERT OPINION ON PHARMACOTHERAPY, 2021, 22 (06) : 667 - 675
  • [33] Mutation analysis of circulating tumour DNA from baseline and study discontinuation samples in SANDPIPER, a phase III study of taselisib or placebo with fulvestrant in oestrogen receptor-positive, human epidermal growth factor receptor 2-negative, PIK3CA-mutant advanced breast cancer
    Jacot, W.
    Savage, H. M.
    Dent, S.
    Cortes, J.
    Im, Y-H.
    Dieras, V. C.
    Harbeck, N.
    Krop, I. E.
    Chen, J.
    Sokol, E.
    Schimmoller, F.
    Hsu, J.
    De Laurentiis, M.
    Wilson, T. R.
    ANNALS OF ONCOLOGY, 2020, 31 : S16 - S16
  • [34] A phase I/Ib study of inavolisib (GDC-0077) in combination with fulvestrant in patients (pts) with PIK3CA-mutated hormone receptor-positive/HER2-negative (HR+/HER2-) metastatic breast cancer
    Juric, Dejan
    Bedard, Phillippe L.
    Cervantes, Andres
    Gambardella, Valentina
    Oliveira, Mafalda
    Saura, Cristina
    Kalinsky, Kevin M.
    Hamilton, Erika
    Italiano, Antoine
    Krop, Ian E.
    Schmid, Peter
    Turner, Nicholas C.
    Varga, Andrea
    Royer-Joo, Stephanie
    Hutchinson, Katherine E.
    Schutzman, Jennifer L.
    Jhaveri, Komal L.
    CANCER RESEARCH, 2022, 82 (04)
  • [35] LORELEI: A phase II randomized, double-blind study of neoadjuvant letrozole plus taselisib (GDC-0032) versus letrozole plus placebo in postmenopausal women with ER-positive/HER2-negative, early-stage breast cancer
    Oliveira, M.
    de Azambuja, E.
    Saura, C.
    Dubsky, P.
    Zardavas, D.
    Fesl, C.
    Bardia, A.
    Soberino, J.
    Gil, E. Ciruelos
    Ng, V.
    Fredrickson, J.
    Stout, T. J.
    Singel, S. M.
    Hsu, J. Y.
    Piccart, M.
    Gnant, M.
    Baselga, J.
    CANCER RESEARCH, 2016, 76
  • [36] Clinical Significance of PIK3CA and ESR1 Mutations in Circulating Tumor DNA: Analysis from the MONARCH 2 Study of Abemaciclib plus Fulvestrant (vol 28, pg 1500, 2022)
    Tolaney, Sara M.
    Toi, Masakazu
    Neven, Patrick
    Sohn, Joohyuk
    Grischke, Eva-Maria
    Llombart-Cussac, Antonio
    Soliman, Hatem
    Wang, Hong
    Wijayawardana, Sameera
    Jansen, Valerie M.
    Litchfield, Lacey M.
    Sledge, George W., Jr.
    CLINICAL CANCER RESEARCH, 2022, 28 (20) : 4587 - 4587
  • [37] Phase II Trial of Fulvestrant With Metronomic Capecitabine for Postmenopausal Women With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer
    Schwartzberg, Lee S.
    Wang, Grace
    Somer, Bradley G.
    Blakely, L. Johnetta
    Wheeler, Benton M.
    Walker, Mark S.
    Stepanski, Edward J.
    Houts, Arthur C.
    CLINICAL BREAST CANCER, 2014, 14 (01) : 13 - 19
  • [38] Phase III study of GDC-0077 or placebo (pbo) with palbociclib (P) plus fulvestrant (F) in patients with PIK3CA-mutant/hormone receptor-positive/HER2-negative locally advanced or metastatic breast cancer (HR+/HER2-LA/MBC)
    Turner, Nicolas
    Jhaveri, Komal
    Kalinsky, Kevin
    Loibl, Sibylle
    Loi, Sherene
    Im, Seock-Ah
    Saura, Cristina
    Schmid, Peter
    Schutzman, Jennifer L.
    Stout, Thomas J.
    Lei, Guiyuan
    Hutchinson, Katherine E.
    Thanopoulou, Eirini
    Juric, Dejan
    CANCER RESEARCH, 2021, 81 (04)
  • [39] Clinical significance of PIK3CA, AKT1, and ESR1 mutation in plasma cell-free DNA from estrogen receptor-positive breast cancer patients
    Takeshita, Takashi
    Tomiguchi, Mai
    Sueta, Aiko
    Yamamoto-Ibusuki, Mutsuko
    Yamamoto, Yutaka
    Iwase, Hirotaka
    CANCER RESEARCH, 2018, 78 (13)
  • [40] A phase I/Ib study evaluating GDC-0077+palbociclib (palbo) plus fulvestrant in patients (pts) with PIK3CA-mutant (mut), hormone receptor-positive/HER2-negative metastatic breast cancer (HR+/HER2-mBC)
    Bedard, Philippe L.
    Jhaveri, Komal
    Cervantes, Andres
    Gambardella, Valentina
    Hamilton, Erika
    Italiano, Antoine
    Kalinsky, Kevin
    Krop, Ian E.
    Oliveira, Mafalda
    Saura, Cristina
    Schmid, Peter
    Turner, Nicolas
    Varga, Andrea
    Hutchinson, Katherine E.
    Lei, Guiyuan
    Royer-Joo, Stephanie
    Thomas, Piia
    Schutzman, Jennifer L.
    Juric, Dejan
    CANCER RESEARCH, 2021, 81 (04)
12345